ArticleFrontiers in physiology2026
Machine learning-selected inflammation biomarkers for stable coronary artery disease with intermediate coronary lesions: potential for long-term prognosis in a multicenter cohort study.
Article in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Stable coronary artery disease (SCAD) generally exhibits prolonged periods of stability. However, this condition can unpredictably progress into an unstable state, representing a complex pathological process involving multiple contributing factors. Thus, we aimed to utilize machine-learning techniques to identify predictive features from electronic health record (EHR) data for forecasting the long-term prognosis of patients with SCAD and intermediate coronary lesions. Methods: Patients were divided into a training cohort (n = 403) and an external validation cohort (n = 247) according to their hospital of origin during the period from January 2018 to December 2020. Predictive features were determined using LASSO regression analysis and boruta algorithm, followed by multivariate Cox regression analysis for model construction. Results: The developed predictive model comprised four clinical variables: platelet-to-lymphocyte ratio, diabetes mellitus, lipoprotein(a), and mean platelet width. The area under the curve for predicting major adverse cardiovascular events (MACEs) within 2-, 3- and 4-year in the development cohort was 0.692 (95%CI:0.59-0.793), 0.709 (95%CI:0.625-0.792) and 0.743 (95%CI:0.672-0.813), respectively, while that in the external validation cohort was 0.658 (95%CI 0.542-0.773), 0.681 (95%CI:0.579-0.782) and 0.723 (95%CI: 0.635-0.811), respectively. Additionally, the developed predictive model was calibrated by analyzing the correlation between expected and observed MACEs in the development and external validation cohorts. Lastly, the clinical value of the developed predictive model was confirmed via decision curve analysis. Conclusion: Our validated nomogram was based on inflammation biomarkers and EHR data, demonstrating moderate discriminative ability to detect individuals at high risk of poor outcome among patients with SCAD and angiographically intermediate coronary stenosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.